A standalone M&A theme involving the acquisition of Visterra as a wholly owned subsidiary, together with the Hierotope® platform for computational antibody structure design and an antibody drug pipeline including VIS649. The acquisition of an antibody drug discovery technology platform and clinical development candidates is intended to strengthen drug discovery research and development capabilities.